William Blair Issues Optimistic Forecast for Biogen Earnings

Biogen Inc. (NASDAQ:BIIB) – Investment analysts at William Blair lifted their FY2024 EPS estimates for shares of Biogen in a note issued to investors on Wednesday, October 30th. William Blair analyst M. Minter now anticipates that the biotechnology company will earn $16.36 per share for the year, up from their prior estimate of $15.92. The consensus estimate for Biogen’s current full-year earnings is $16.36 per share. William Blair also issued estimates for Biogen’s Q3 2025 earnings at $3.47 EPS and FY2025 earnings at $14.94 EPS.

Several other research firms also recently commented on BIIB. HC Wainwright restated a “buy” rating and issued a $300.00 price target on shares of Biogen in a research note on Thursday. Mizuho dropped their price target on shares of Biogen from $277.00 to $251.00 and set an “outperform” rating for the company in a research report on Tuesday, August 6th. TD Cowen reduced their price target on Biogen from $300.00 to $275.00 and set a “buy” rating on the stock in a research report on Thursday. Wells Fargo & Company dropped their price objective on Biogen from $240.00 to $225.00 and set an “equal weight” rating for the company in a report on Friday, August 2nd. Finally, Robert W. Baird decreased their price target on Biogen from $316.00 to $294.00 and set an “outperform” rating on the stock in a research report on Monday, July 29th. Ten research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Biogen currently has an average rating of “Moderate Buy” and a consensus price target of $262.83.

Biogen Stock Down 0.1 %

BIIB stock opened at $173.79 on Monday. Biogen has a fifty-two week low of $173.14 and a fifty-two week high of $268.30. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.26 and a quick ratio of 1.48. The stock has a market capitalization of $25.32 billion, a price-to-earnings ratio of 15.70, a PEG ratio of 1.73 and a beta of -0.06. The business’s fifty day moving average price is $192.71 and its two-hundred day moving average price is $209.59.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $4.08 EPS for the quarter, beating the consensus estimate of $3.77 by $0.31. The company had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.43 billion. Biogen had a return on equity of 14.98% and a net margin of 16.81%. The firm’s revenue for the quarter was down 2.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.36 earnings per share.

Institutional Trading of Biogen

A number of institutional investors and hedge funds have recently bought and sold shares of BIIB. Vanguard Group Inc. grew its position in shares of Biogen by 15.0% in the 1st quarter. Vanguard Group Inc. now owns 16,570,398 shares of the biotechnology company’s stock valued at $3,573,075,000 after buying an additional 2,163,068 shares during the last quarter. Primecap Management Co. CA boosted its holdings in Biogen by 0.7% in the second quarter. Primecap Management Co. CA now owns 16,338,294 shares of the biotechnology company’s stock valued at $3,787,543,000 after acquiring an additional 117,578 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Biogen by 5.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,589,629 shares of the biotechnology company’s stock valued at $342,772,000 after purchasing an additional 81,283 shares during the period. RA Capital Management L.P. raised its holdings in Biogen by 39.0% during the 1st quarter. RA Capital Management L.P. now owns 740,727 shares of the biotechnology company’s stock worth $159,723,000 after purchasing an additional 207,835 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of Biogen by 27.2% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 570,533 shares of the biotechnology company’s stock worth $123,024,000 after purchasing an additional 122,101 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider Priya Singhal sold 431 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $204.22, for a total transaction of $88,018.82. Following the completion of the transaction, the insider now owns 5,316 shares of the company’s stock, valued at approximately $1,085,633.52. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.